Dasher Neuroscience Completes Patient Enrollment in Phase 2 Global Clinical Trial of Lead AI Drug Candidate YA-101 for Multiple System Atrophy (MSA)

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Dasher-MSA-

More Like This

Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025

Exidavnemab phase 2a study expanded to include MSA patients

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

ACCESS Newswire logo

Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant

BioArctic receives Orphan Drug Designation for exidavnemab the US

Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston

Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting